专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008007211A1 SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS 审中-公开
标题翻译：取代的N-双羟基苄基双环羧酰胺化合物
公开(公告)号：WO2008007211A1
公开(公告)日：2008-01-17
申请号：PCT/IB2007001984
申请日：2007-07-02
申请人： PFIZER JAPAN INC , PFIZER , KAWASHIMA TADASHI , NAGAYAMA SATOSHI , NAKAO KAZUNARI , TANAKA HIROTAKA
发明人： KAWASHIMA TADASHI , NAGAYAMA SATOSHI , NAKAO KAZUNARI , TANAKA HIROTAKA
IPC分类号： C07D209/34 , A61K31/395 , A61P25/00 , C07D215/06 , C07D231/56 , C07D249/18 , C07D403/12
CPC分类号： C07D209/34 , C07D215/06 , C07D231/56 , C07D249/18 , C07D403/12
摘要： This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供式（I）化合物及其用于治疗哺乳动物VR1受体过度活化（如疼痛等）引起的疾病状况。本发明还提供了包含上述化合物的药物组合物。

2. 发明申请

WO2007133637A3 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME 审中-公开
标题翻译：作为离子通道配体和药物组合物的酰胺衍生物及其使用方法
公开(公告)号：WO2007133637A3
公开(公告)日：2008-01-03
申请号：PCT/US2007011310
申请日：2007-05-10
申请人： RENOVIS INC , PFIZER , SHISHIDO YUJI , NAKAO KAZUNARI , NAGAYAMA SATOSHI , TANAKA HIROTAKA , DUNCTON MATTHEW ALEXANDER JAME , COX MATTHEW , KINCAID JOHN , SAHASRABUDHE KIRAN , ESTIARTE-MARTINEZ MARIA DE LOS
发明人： SHISHIDO YUJI , NAKAO KAZUNARI , NAGAYAMA SATOSHI , TANAKA HIROTAKA , DUNCTON MATTHEW ALEXANDER JAME , COX MATTHEW , KINCAID JOHN , SAHASRABUDHE KIRAN , ESTIARTE-MARTINEZ MARIA DE LOS
IPC分类号： A61K31/497
CPC分类号： C07D215/48 , C07C311/08 , C07C2601/02 , C07D205/04 , C07D215/54 , C07D217/26 , C07D231/12 , C07D239/94 , C07D241/44 , C07D295/155 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/12 , C07D471/04 , C07D498/04 , C07D498/12
摘要： Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
摘要翻译：公开了具有由下式表示的式的化合物：式（I）。化合物可以制备成药物组合物，并且可以用于预防和治疗包括人在内的哺乳动物中的各种病症，包括作为非限制性实例，疼痛，炎症，创伤性损伤等。

3. 发明申请

WO2005105733A1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS 审中-公开
标题翻译： ORTHO取代的芳基或杂芳基化合物
公开(公告)号：WO2005105733A1
公开(公告)日：2005-11-10
申请号：PCT/IB2005/001135
申请日：2005-04-22
申请人： PFIZER JAPAN INC. , PFIZER INC. , KOIKE, Hiroki , MATSUMOTO, Yukari , YAMAGISHI, Tatsuya , OKUMURA, Yoshiyuki , NAKAO, Kazunari
发明人： KOIKE, Hiroki , MATSUMOTO, Yukari , YAMAGISHI, Tatsuya , OKUMURA, Yoshiyuki , NAKAO, Kazunari
IPC分类号： C07C235/60
CPC分类号： C07D261/08 , C07C235/60 , C07C255/54 , C07C2601/04 , C07C2601/14 , C07D213/61 , C07D213/82 , C07D213/89 , C07D307/12 , C07D307/42 , C07D309/06 , C07D405/12
摘要： The invention provides a compound of the formula (I): wherein X represents a carbon atom or the like : Y represents imino, or the like: Z represents a hydrogen atom or the like: R 1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R 2 and R 3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供式（I）的化合物：其中X表示碳原子等：Y表示亚氨基等：Z表示氢原子等：R 1表示具有1个至6个碳原子等：R 2和R 3独立地表示氢原子等。这些化合物可用于治疗由前列腺素介导的疾病状况，例如哺乳动物中的疼痛等。本发明还提供了包含上述化合物的药物组合物。

4. 发明申请

WO2007129188A1 CYCLOPROPANECARBOXAMIDE COMPOUND 审中-公开
标题翻译：环磷酰胺化合物
公开(公告)号：WO2007129188A1
公开(公告)日：2007-11-15
申请号：PCT/IB2007/001143
申请日：2007-04-27
申请人： PFIZER JAPAN INC. , PFIZER INC. , HANAZAWA, Takeshi , NAGAYAMA, Satoshi , NAKAO, Kazunari , SHISHIDO, Yuji , TANAKA, Hirotaka
发明人： HANAZAWA, Takeshi , NAGAYAMA, Satoshi , NAKAO, Kazunari , SHISHIDO, Yuji , TANAKA, Hirotaka
IPC分类号： C07D213/24 , A61K31/435 , A61P29/00
CPC分类号： C07D213/24
摘要： This invention relates to novel substituted N-(N-sulfonylaminoarylmethyl)cyclopropanecarboxamide compound and to their use in therapy. This invention provides 2-(6-tert-butylpyridin-3-yl)-N-((1R)-1-{3,5-difluoro-4-[(methylsulfonyl)amino]phenyl}ethyl)-2-methylcyclopropanecarboxamide, or a pharmaceutically acceptable salt or solvate thereof. This compound is particularly useful as an antagonist of the VR1 (Type I Vanilloid) receptor, and is thus useful for the treatment of pain, neuralgia, neuropathies, nerve injury, burns, migraine, carpal tunnel syndrome, fibromyalgia, neuritis, sciatica, pelvic hypersensitivity, bladder disease, inflammation, or the like in mammals, especially humans. The present invention also relates to a pharmaceutical composition comprising the above compound.
摘要翻译：本发明涉及新的取代的N-（N-磺酰基氨基芳基甲基）环丙烷甲酰胺化合物及其在治疗中的用途。本发明提供2-（6-叔丁基吡啶-3-基）-N - （（1R）-1- {3,5-二氟-4 - [（甲基磺酰基）氨基]苯基}乙基）-2-甲基环丙烷甲酰胺，或其药学上可接受的盐或溶剂合物。该化合物特别可用作VR1（I型香草素）受体的拮抗剂，因此可用于治疗疼痛，神经痛，神经病，神经损伤，烧伤，偏头痛，腕管综合征，纤维肌痛，神经炎，坐骨神经痛，骨盆哺乳动物，特别是人类中的超敏反应，膀胱疾病，炎症等。本发明还涉及包含上述化合物的药物组合物。

5. 发明申请

WO2006095263A8 SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS 审中-公开
标题翻译：取代的N-磺酰氨基苯乙烯基-2-苯氧基乙酰胺化合物
公开(公告)号：WO2006095263A8
公开(公告)日：2007-11-08
申请号：PCT/IB2006000539
申请日：2006-02-24
申请人： PFIZER JAPAN INC , PFIZER , HANAZAWA TAKESHI , HIRANO MISATO , INOUE TADASHI , NAGAYAMA SATOSHI , NAKAO KAZUNARI , SHISHIDO YUJI , TANAKA HIROTAKA
发明人： HANAZAWA TAKESHI , HIRANO MISATO , INOUE TADASHI , NAGAYAMA SATOSHI , NAKAO KAZUNARI , SHISHIDO YUJI , TANAKA HIROTAKA
IPC分类号： C07D295/08 , A61K31/18 , A61K31/353 , A61K31/4453 , A61P25/00 , C07C311/08 , C07D311/58
CPC分类号： C07C311/08
摘要： This invention provides a compound of the formula (I), wherein R 1 represents (C 1 -C 6 )alkyl; R 2 represents a hydrogen atom, a halogen atom, a hydroxy group, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl or halo(C 1 -C 6 )alkyl; R 3 represents a halogen atom, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyll, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 C 6 )alkyllsulfonyl, [(C 1 -C 6 )alkyl]NH-, or [(C 1 -C 6 ) alkyl] 2 N-; R 4 represents a halogen atom, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl]NH-, or [(C 1 -C 6 )alkyl] 2 N-; R 5 represents a halogen atom, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyll, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkyIsulfonyl, [(C 1 -C 6 )alkyl]NH-, [(C 1 -C 6 ) alkyl] 2 N-, H 2 N-(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-NH-(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy, H 2 N-(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl-NH-(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, or [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl; and *indicates a chiral centre; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供式（I）化合物，其中R 1表示（C 1 -C 6 -C 6）烷基; R 2表示氢原子，卤素原子，羟基，（C 1 -C 6 -C 6）烷基，（C 1 -C 6）（C 1 -C 6）烷基，（C 1 -C 6）烷基，（C 1 -C 6）烷基，（C 1 -C 6） C 1 -C 6烷氧基 - （C 1 -C 6 -C 6）烷基或卤代（C 1 -C 6 - ç_{6 ）烷基; R 3表示卤素原子，（C 1 -C 6 -C 6）烷基，（C 1 -C 6 - （C 1 -C 6）烷氧基，（C 1 -C 6）烷氧基，（C 1 -C 6）烷氧基，（C 1 -C 6）烷基，（C 1 -C 6）烷基，（C 1 -C 6）烷基，）烷氧基 - （C 1 -C 6 -C 6）烷氧基，卤素（C 1 -C 6 -C 6）烷基，（C 1 -C 6 -C 6）烷硫基，（C 1 -C 6 -C 6）烷基亚磺酰基，（C _{2 N-; R 5表示卤素原子，（C 1 -C 6 -C 6）烷基，（C 1 -C 6 - （C 1 -C 6）烷氧基，（C 1 -C 6）烷氧基，（C 1 -C 6）烷氧基，（C 1 -C 6）烷基，（C 1 -C 6）烷基，（C 1 -C 6）烷基，）烷氧基 - （C 1 -C 6 -C 6）烷氧基，卤素（C 1 -C 6 -C 6）烷基，（C 1 -C 6 -C 6）烷硫基，（C 1 -C 6 -C 6）烷基亚磺酰基，（C _{C 6 -C 6烷基） C 1 -C 6烷基] N 2 - ， - N - （C 1 -C 6） C 1 -C 6烷氧基，（C 1 -C 6 -C 6）烷基-NH-（C 1 -C 6） -C 6 -C 6烷氧基，[（C 1 -C 6 -C 6）烷基] N 2 N（C < C 1 -C 6 -C 6烷氧基，H 2 N - （C 1 -C 6））烷氧基 - （C 1 -C 6 -C 6）烷基，（C 1 -C 6 -C 6）烷基-NH - （C 1 -C 6 -C 6）烷氧基 - （C 1 -C 6 -C 6）烷基或[（ ç_{1 -C _{6 ）烷基] _{2 N（ç_{1 -C _{6 ）烷氧基 - （C _{1 < / SUB> -C _{6 ）烷基; 和*表示手性中心; 或其药学上可接受的盐或溶剂合物。这些化合物可用于治疗由哺乳动物中VR1受体过度活化引起的疼痛等疼痛引起的疾病状况。本发明还提供了包含上述化合物的药物组合物。}}}}}}}}}}

6. 发明申请

WO2005105732A8 SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS 审中-公开
标题翻译：取代的甲基或芳基化合物
公开(公告)号：WO2005105732A8
公开(公告)日：2007-04-19
申请号：PCT/IB2005001134
申请日：2005-04-22
申请人： PFIZER JAPAN INC , PFIZER , KOIKE HIROKI , MATSUMOTO YUKARI , YAMAGISHI TATSUYA , KON-I KANA , OKUMURA YOSHIYUKI , NAKAO KAZUNARI
发明人： KOIKE HIROKI , MATSUMOTO YUKARI , YAMAGISHI TATSUYA , KON-I KANA , OKUMURA YOSHIYUKI , NAKAO KAZUNARI
IPC分类号： C07C235/42 , A61K31/195 , A61K31/455 , C07C235/46 , C07C235/70 , C07D213/56 , C07D213/65 , C07D213/74 , C07D213/82 , C07D213/89
CPC分类号： C07D213/74 , C07C235/42 , C07C235/46 , C07C2601/08 , C07C2601/14 , C07D213/65 , C07D213/82 , C07D213/89
摘要： This invention provides a compound of the formula (I), wherein X represents a carbon atom or the like: Y represents imino, or the like: R 1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R 2 and R 3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供式（I）化合物，其中X表示碳原子等：Y表示亚氨基等：R 1表示具有1至6个碳原子的烷基 R 2，R 3和R 3独立地表示氢原子等。这些化合物可用于治疗由前列腺素介导的疾病状况，例如哺乳动物中的疼痛等。本发明还提供了包含上述化合物的药物组合物。

7. 发明申请

WO2006097817A9 N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN 审中-公开
标题翻译：用于治疗疼痛的N-（N-磺酰基氨基甲基）环丙烷氨基甲酰胺衍生物
公开(公告)号：WO2006097817A9
公开(公告)日：2006-12-07
申请号：PCT/IB2006000557
申请日：2006-03-07
申请人： PFIZER JAPAN INC , PFIZER , HANAZAWA TAKESHI , HIRANO MISATO , INOUE TADASHI , NAGAYAMA SATOSHI , NAKAO KAZUNARI , SHISHIDO YUJI , TANAKA HIROTAKA
发明人： HANAZAWA TAKESHI , HIRANO MISATO , INOUE TADASHI , NAGAYAMA SATOSHI , NAKAO KAZUNARI , SHISHIDO YUJI , TANAKA HIROTAKA
IPC分类号： C07C311/08 , A61K31/145 , A61K31/44 , A61P29/00 , C07C317/44 , C07C323/62 , C07D213/56 , C07D213/74 , C07D213/76
CPC分类号： C07C61/28 , C07C61/40 , C07C311/08 , C07C317/44 , C07C323/62 , C07C2601/02 , C07D213/26 , C07D213/56 , C07D213/74 , C07D213/76
摘要： This invention provides a compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compounds.
摘要翻译：本发明提供了式（I）化合物或其药学上可接受的盐或溶剂化物。这些化合物可用于治疗由VR1受体的过度激活引起的疾病状态，例如哺乳动物的疼痛等。本发明还提供了包含上述化合物的药物组合物。

8. 发明申请

WO2006016218A1 ARYL OR HETEROARYL CARBONYL DERIVATIVES DERIVATIVES USEFUL AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS 审中-公开
标题翻译：作为VANILLOID受体1（VR1）拮抗剂有用的ARYL或HETEROARYL CARBONYL衍生物衍生物
公开(公告)号：WO2006016218A1
公开(公告)日：2006-02-16
申请号：PCT/IB2005/002183
申请日：2005-07-21
申请人： PFIZER JAPAN INC. , PFIZER INC. , MIYAKE, Yoriko , NAGAYAMA, Satoshi , NAKAO, Kazunari , SUDO, Masaki , TANAKA, Hirotaka
发明人： MIYAKE, Yoriko , NAGAYAMA, Satoshi , NAKAO, Kazunari , SUDO, Masaki , TANAKA, Hirotaka
IPC分类号： C07C235/78 , C07D213/50 , C07D277/20 , C07D233/54 , A61K31/16 , A61K31/4164 , A61K31/44 , A61K31/426
CPC分类号： C07D277/20 , C07C235/20 , C07D213/50 , C07D233/54
摘要： This invention provides a compound of the formula (I): wherein R 1 and R 2 independently represent hydrogen or (C 1 -C 6 )alkyl or the like; R 3 and R 4 independently represent hydrogen or (C 1 -C 3 )alkyl; n represents 1 or 2; A represents phenyl or a monocyclic heteroaryl having from 5 to 6 atoms or the like; and R 5 and R 6 each independently represent halogen, (C 1 -C 6 )alkyl, cyano, hydroxy, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl and (C 1 -C 6 )alkylsulfonyl; or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供式（I）的化合物：其中R

9. 发明申请

WO2003086390A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS 审中-公开
标题翻译：咪唑化合物作为抗炎和灭菌剂
公开(公告)号：WO2003086390A1
公开(公告)日：2003-10-23
申请号：PCT/IB2003/001275
申请日：2003-04-02
申请人： PFIZER PHARMACEUTICALS INC. , PFIZER INC. , HIRANO, Misato , IGUCHI, Satoru , NAKAO, Kazunari , YAMAGISHI, Tatsuya
发明人： HIRANO, Misato , IGUCHI, Satoru , NAKAO, Kazunari , YAMAGISHI, Tatsuya
IPC分类号： A61K31/4164
CPC分类号： C07D233/64 , C07D233/88 , C07D235/08 , C07D401/12 , C07D521/00
摘要： This invention provides a compound of the formula (1) wherein: R 1 represents a hydrogen atom, an alkyl group, etc.; R 2 represents a hydrogen atom, a halogen atom, etc.; R 3 represents a hydrogen atom, an alkyl group, etc.; R 4 represents an aryl group, etc.; A represents an aryl 1 , etc; B represents an alkylene etc.; X represents NH, etc.; or a phannaceutically acceptable ester of such compound, and pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of medical conditions mediated by prostaglandins such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供式（1）的化合物，其中：R 1表示氢原子，烷基等; R 2表示氢原子，卤素原子等; R 3表示氢原子，烷基等; R 4表示芳基等; A表示芳基等; B表示亚烷基等。 X表示NH等。或这种化合物的药学上可接受的酯及其药学上可接受的盐。这些化合物可用于治疗前列腺素介导的医疗状况，例如疼痛，发热或炎症等。本发明还提供包含上述化合物的药物组合物。

10. 发明申请

WO0232900A3 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS 审中-公开
标题翻译： ARYL或HETEROARYL融合咪唑类化合物作为抗炎和镇痛药
公开(公告)号：WO0232900A3
公开(公告)日：2002-08-08
申请号：PCT/IB0101940
申请日：2001-10-15
申请人： PFIZER PHARMA , NAKAO KAZUNARI , OKUMURA YOSHIYUKI , MATSUMIZU MIYAKO , UNEO NAOMI , HASHIZUME YOSHINOBU , KATO TOMOKI , KAWAI AKIYOSHI , MIYAKE YORIKO , PFIZER , NUKUI SEIJI , SHINJYO KATSUHIRO , TANIGUCHI KANA
发明人： NAKAO KAZUNARI , OKUMURA YOSHIYUKI , MATSUMIZU MIYAKO , UNEO NAOMI , HASHIZUME YOSHINOBU , KATO TOMOKI , KAWAI AKIYOSHI , MIYAKE YORIKO , NUKUI SEIJI , SHINJYO KATSUHIRO , TANIGUCHI KANA
IPC分类号： G01N33/48 , A61K31/00 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4725 , A61K31/506 , A61K31/52 , A61K31/64 , A61K45/00 , A61P1/00 , A61P1/02 , A61P1/04 , A61P3/10 , A61P5/00 , A61P7/02 , A61P7/04 , A61P7/08 , A61P9/00 , A61P9/10 , A61P9/12 , A61P9/14 , A61P11/02 , A61P11/06 , A61P13/12 , A61P15/04 , A61P15/06 , A61P17/00 , A61P17/02 , A61P17/16 , A61P19/02 , A61P19/06 , A61P19/08 , A61P19/10 , A61P21/00 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/06 , A61P25/20 , A61P25/28 , A61P27/00 , A61P27/06 , A61P29/00 , A61P31/12 , A61P31/16 , A61P31/18 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P41/00 , A61P43/00 , C07D235/06 , C07D235/08 , C07D235/10 , C07D235/12 , C07D235/14 , C07D235/16 , C07D235/30 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D473/00 , C07D491/04 , C07D491/048 , C07D491/056 , C07D521/00 , G01N33/15 , G01N33/50
CPC分类号： C07D213/75 , A61K31/00 , A61K31/4178 , A61K31/437 , A61K31/64 , C07D231/12 , C07D233/56 , C07D235/06 , C07D235/08 , C07D235/12 , C07D235/14 , C07D235/16 , C07D235/18 , C07D235/30 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D473/00 , C07D491/04 , Y02P20/55
摘要： This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y , Y , Y , and Y are independently selected from N, CH, etc.; R is H, C1-8 alkyl, etc.; Q is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R is H, C 1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is o,1 or 2; R and R are independently selected from H and C1-4 alkyl; R is H, C1-4 alkyl, etc.; Q is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供了式（I）化合物或其药学上可接受的盐，其中Y 1，Y 2，Y 3和Y 4独立地选自N，CH等 ; R 1是H，C 1-8烷基等; Q 1是任选含有至多4个选自O，N和S等的杂原子的5-12元单环或双环芳族环; A是任选地含有至多3个选自O，N和S等的杂原子的5-6元单环芳族环; B是任选被氧代基团取代的C1-6亚烷基等; W是NH，O等; R 2是H，C 1-4烷基等; Z为任选含有至多3个选自O，N和S等的杂原子的5-12元单环或双环芳族环; L为卤素，C 1-4烷基等; m是0,1或2; R 3和R 4独立地选自H和C 1-4烷基; R 5是H，C 1-4烷基等; Q 2是任选含有至多3个选自O，N和S的杂原子的5-12元单环或双环芳族环或三环等。这些化合物可用于治疗前列腺素介导的医学病症，例如疼痛，发热或炎症等。本发明还提供包含上述化合物的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式